{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-017132","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.063567+00:00","generated_at":"2026-06-01T22:32:22.955033+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CervoMed reports Q1 net income $2.5M; DLB trial enrollment on track for Q2 2024","bullets":["Cash $6.4M as of March 31; plus $50M upfront from private placement closed April 1 provides runway through end 2025.","RewinD-LB Phase 2b enrollment on track to complete in Q2 2024; topline data expected Q4 2024.","Net income $2.5M in Q1 vs net loss $0.5M in Q1 2023; operating loss widened to $2.6M from $1.4M.","Grant revenue from NIA $2.3M in Q1 vs $1.4M; R&D expenses increased to $2.8M.","Up to $149.4M private placement with leading healthcare investors; $50M gross upfront."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-017132","json":"https://secwatch.observer/filing/0001437749-24-017132.json","markdown":"https://secwatch.observer/filing/0001437749-24-017132.md","text":"https://secwatch.observer/filing/0001437749-24-017132.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924017132/0001437749-24-017132-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924017132/crvo20240515_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:32:22.955033+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"790ad0941c169404fa9cc36a59f6b2fa48e6de16","claim":"CervoMed Inc. reported first quarter ended March 31, 2024 results: net income approximately $2.5 million.","evidence_excerpt":"Net income was approximately $2.5 million for the three months ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924017132/0001437749-24-017132-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"approximately $2.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}